Arecor Therapeutics has "a strong basis to accelerate" growth strategy
News release
by
Arecor Therapeutics PLC
Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Thomas Warner from Proactive after releasing preliminary full-year results for 2022. She gives her take on the highlights from last year before going on to lay out what investors can expect from the business during 2023. Howell says that Arecor has a "strong basis to accelerate" its growth strategy and "plenty to look forward to."
Contact Details
Proactive UK Ltd
+44 20 7989 0813